The Federal Trade Commission on Thursday warned brand-name drug manufacturers against improperly listing patents in the U.S. Food and Drug Administration’s Orange Book and addressed the harm of “blurring” advertisements toward children. 

“We’ve all heard time and time again about how drug prices are just sky high,” FTC Chair Lina Khan said in an open meeting. “We at the FTC are fully committed to using all of our tools to combat corporate misconduct that is unlawfully inflating drug prices.”